登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中国医学科学院肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07560358,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed non-small cell lung cancer (NSCLC);
入选标准第 3 条
Unresectable stage III NSCLC (per AJCC 9th edition staging), with primary tumor diameter T ≥ 5 cm or regional metastatic lymph node short-axis diameter N ≥ 2 cm;
入选标准第 4 条
Participation in another clinical trial within 4 weeks prior to the first study dose or within 5 half-lives of the study drug, whichever is shorter.
排除标准第 3 条
Subjects who have received systemic immunosuppressive therapy within 2 weeks before the first dose, or those who are expected to require systemic immunosuppressive drugs during the study treatment period.
排除标准第 4 条
ECOG performance status score of 0 or 1;
入选标准第 2 条
Subjects with congenital or acquired immunodeficiency, such as HIV infection; or with a history of autoimmune diseases.
排除标准第 5 条
History of other malignant tumors (other than NSCLC) within 5 years prior to screening.
排除标准第 8 条
Female subjects must have a negative pregnancy test result and be willing to use effective contraception;
入选标准第 8 条
History of live attenuated vaccination within 28 days before the first dose, or planned live attenuated vaccination during the study period; pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptive measures.
排除标准第 14 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07560358,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Aged between 18 and 75 years; ECOG performance status score of 0 or 1; Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); Unresectable stage III NSCLC (per AJCC 9th edition staging), with primary tumor diameter T ≥ 5 cm or regional metastatic lymph node short-axis diameter N ≥ 2 cm; Expected survival time of at least 3 months; No prior anti-tumor treatment before enrollment, including radiotherapy, chemotherapy, surgery and targeted therapy; Adequate function of major organs; Female subjects must have a negative pregnancy test result and be willing to use effective contraception; Subjects voluntarily participate in the study, sign the informed consent form, with good compliance and willingness to complete follow-up.排除标准:Exclusion Criteria:
Subjects with known positive EGFR mutation or positive ALK fusion. Histologically or cytologically confirmed mixed SCLC and NSCLC, large cell neuroendocrine carcinoma, and sarcomatoid carcinoma. Participation in another clinical trial within 4 weeks prior to the first study dose or within 5 half-lives of the study drug, whichever is shorter. Subjects who have received systemic immunosuppressive therapy within 2 weeks before the first dose, or those who are expected to require systemic immunosuppressive drugs during the study treatment period. Subjects with congenital or acquired immunodeficiency, such as HIV infection; or with a history of autoimmune diseases. Active hepatitis B, hepatitis C, or co-infection with both hepatitis B and hepatitis C. Uncontrolled third-space effusions, such as massive pleural effusion, ascites or pericardial effusion. History of other malignant tumors (other than NSCLC) within 5 years prior to screening. Subjects with prior interstitial lung disease requiring hormone therapy. Subjects with severe cardiovascular and cerebrovascular diseases. History of severe bleeding events or arterial/venous thromboembolic events. Severe infection within 4 weeks before the first dose; evidence of active tuberculosis infection within 1 year prior to the first dose; active fungal, bacterial and/or viral infections requiring systemic treatment. Subjects with prior or planned allogeneic bone marrow transplantation or solid organ transplantation. History of live attenuated vaccination within 28 days before the first dose, or planned live attenuated vaccination during the study period; pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptive measures. Known hypersensitivity, anaphylactic reaction or intolerance to adebrelimab, chemotherapy agents, or their excipients. Subjects with a known history of psychoactive substance abuse, alcoholism or drug addiction.
引自 ClinicalTrials.gov, NCT07560358, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07560358,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。